{"id":919,"date":"2020-08-26T09:32:18","date_gmt":"2020-08-26T09:32:18","guid":{"rendered":"https:\/\/clinlabint.3wstaging.nl\/siemens-healthineers-has-announced-closing-of-fast-track-diagnostics-acquisition\/"},"modified":"2021-01-08T11:08:53","modified_gmt":"2021-01-08T11:08:53","slug":"siemens-healthineers-has-announced-closing-of-fast-track-diagnostics-acquisition","status":"publish","type":"post","link":"https:\/\/clinlabint.com\/siemens-healthineers-has-announced-closing-of-fast-track-diagnostics-acquisition\/","title":{"rendered":"Siemens Healthineers has announced closing of Fast Track Diagnostics acquisition"},"content":{"rendered":"

FTD\u2019s broad range of CE-marked infectious disease detection tests and syndromic panels expands the Siemens Healthineers menu of assays for its VERSANT\u00ae kPCR Molecular System by over 85 assays and syndromic panels, transforming care delivery for its customers with a comprehensive solution for molecular testing of infectious diseases such as respiratory infections, gastroenteritis, meningitis, hepatitis, infections of the immunosuppressed, tropical diseases, sexually transmitted diseases, and early childhood diseases. In addition, FTD\u2019s platform-agnostic menu allows Siemens Healthineers to effectively serve a broader customer base. <\/p>\n

\u201cThe closing of this deal enables both Siemens Healthineers and FTD\u2014now joined as one\u2014to more effectively address the evolving needs of the molecular diagnostics marketplace,\u201d says Fernando Beils, Head of Molecular Diagnostics, Siemens Healthineers. \u201cIt is an exciting time for us at Siemens Healthineers as we welcome the FTD community into our own.\u201d<\/p>\n

FTD will continue to operate under the brand name Fast Track Diagnostics<\/i> throughout the world.<\/p>\nwww.siemens.com\/healthineers<\/link>\n","protected":false},"excerpt":{"rendered":"

Siemens Healthineers confirmed on January 10, 2018 that it has completed its acquisition of Fast Track Diagnostics (FTD). The closing of the deal occurred on December 19, 2017, expanding the Siemens Healthineers molecular diagnostics portfolio and underscoring the company\u2019s commitment to this designated growth area. Terms of the agreement were not disclosed. FTD\u2019s broad range […]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"categories":[35],"tags":[],"class_list":["post-919","post","type-post","status-publish","format-standard","hentry","category-e-news"],"_links":{"self":[{"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/posts\/919","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/comments?post=919"}],"version-history":[{"count":0,"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/posts\/919\/revisions"}],"wp:attachment":[{"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/media?parent=919"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/categories?post=919"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/tags?post=919"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}